Search Results

April 2022 Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage platform and enhancing translational medicine capabilities • ‘Venture-like’ capital allocation approach Chris Cargill appointed as President and Chief Executive Officer • Dr. Matt Barnes appointed President of Heptares Therapeutics Ltd., and Head of UK R&D Tokyo, Japan and Cambridge Corporation (“the Company”; TSE: 4565) today confirms that a series of Executive Management changes have been approved

April 2022 Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 Addex Expands Pipeline With Selective M4 Positive Allosteric Modulator Program For The Treatment Allosteric Modulator Screening Platform Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April

April 2022 Addex Therapeutics Completes Patient Enrollment For Dipraglurant Blepharospasm Phase 2 Clinical Study "Geneva, Switzerland, April 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage

CFTX-1554 is being developed as a non-opioid approach to the treatment of neuropathic pain, a debilitating

Explicyte, an expert in the field of IO and innovative target identification through multiparametric approaches

You can also leave us a review on Apple Podcast!

It captures our values and vision for the future, our culture, and our unique approach to science.

improve the folding and stability of the mutant receptor is one of the most promising pharmacological approaches

mechanical and/or pharmacological activation of endogenous Ca2+ signaling transducers; however, such approaches

development and wing expansion and maturation in H. cunea, suggesting HLGR2 is a promising candidate for application

Applying this molecular tool in a membrane-based setup and in living cells, we discovered a 4-aminopyrimidine succeeded in showing that our CCR9-PROTAC is able to reduce CCR9 levels, thereby offering an unprecedented approach

receptors (GPCRs), a large class of signaling proteins exemplified by the visual receptor rhodopsin and its apoprotein

located at cognate positions across GPCR paralogs opens a window into cancer mechanisms and potential approaches

Although several GPCRs have been studied in astrocytes using a chemogenetic approach, the functional

Microiontophoretically applied H1152, a ROCK inhibitor, and siRNA-induced ROCK2 knockdown both depressed

With appreciable D2LR and D4R agonism and D1R antagonism, kurarinone might be a potential compound that

Specifically controlling the activity of GPCR dimers with ligands is a good approach to clarify their

acute metabolic effects following agonist activation of β2-adrenergic and, potentially, CRF2 receptors appear

for 2-iodomelatonin, a nonselective agonist with a slower dissociation rate from the MT2 receptor, applying

The islets of Langerhans are central to appropriate glucose homeostasis through their secretion of insulin

Application of mesenchymal stem cells (MSCs) as an emerging approach was recruited forthe treatment of in the recruitment and oriented trafficking of immune cells both towards and within the CNS and it appears

APRIL 06 - 09, 2022 | | SNOWBIRD RESORT, UTAH, UNITED STATES The superfamily of G protein-coupled receptors New approaches to GPCR drug discovery.

Here we demonstrate that a similar approach can be employed to rescue mutant follicle-stimulating hormone

In this review, we outline some key NMR techniques applied for on-cell NMR studies through both solution In particular, we focus on the application of on-cell NMR spectroscopy to characterize ligand interactions We also provide a brief survey of the applicability of on-cell NMR approaches to other classes of cell

While no drugs targeting LPARs have been approved by the FDA thus far, at least three antagonists have

such tools is available, only few freely accessible examples teach underlying concepts focused on CADD applications

December 2021 "30/11/2021 Confo will work together with Regeneron to apply its GPCR drug discovery platform ConfoBodies® – to stabilize GPCRs (G protein-coupled receptors) in disease-relevant conformations, will be applied

November 2021 "November 11, 2021 7:00am EST Patricia Drake appointed new Chief Commercial Officer CHESTERBROOK

As a result, most approved library-derived antibodies originate from just three libraries.